4 completed, 1 active not recruiting, 1 not yet recruiting, 1 recruiting. 4 Phase 4, 2 Phase 1, 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 4 | Completed 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Not applicable | 1 | Completed 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Reversal of Neuromuscular Blockade: new trials by email Literature Review of Reversal of Neuromuscular Blockade trials Research Report on Reversal of Neuromuscular Blockade
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Single Ascending Dose of HRS-2162 in Healthy Subjects HRS-2162, Placebo - Reversal of Neuromuscular Blockade | Phase 1 | Completed | Fujian Shengdi Pharmaceutical Co., Ltd. | 8 | 2025-09-25 | 2026-09-22 |
| Reversal of Pipecuronium-induced Neuromuscular Blockade With Sugammadex During Sevoflurane Anesthesia pipecuronium bromide, Rocuronium bromide - Neuromuscular Blocking Agents, Residual Neuromuscular Block | Phase 4 | Not yet recruiting | Tamas Vegh, MD | 80 | 2025-06-26 | 2025-06-29 |
| Reversal of Pipecuronium-induced Neuromuscular Blockade With Sugammadex During Propofol Anesthesia pipecuronium bromide, Rocuronium bromide - Neuromuscular Blocking Agents, Residual Neuromuscular Block | Phase 4 | Active not recruiting | Tamas Vegh, MD | 80 | 2025-06-26 | 2025-08-07 |
| Recovery Times of Half Dose Sugammadex and Neostigmine for Rocuronium-induced Neuromuscular Blockade Sugammadex 1 mg/kg, Neostigmine + Atropine - Neuromuscular Blocking Agents, Reversal of Neuromuscular Blockade | Phase 1 / Phase 2 | Recruiting | Universitas Padjadjaran | 60 | 2024-11-05 | 2025-01-28 |
| Efficacy and Safety of Sugammadex in Thoracoscopy Thymectomy for Chinese Adults With Myasthenia Gravis Sugammadex, Neostigmine - Reversal of Neuromuscular Blockade | Not applicable | Completed | Beijing Tongren Hospital | 62 | 2024-06-01 | 2025-04-02 |
| Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine Surgery Sugammadex, Neostigmine, Glycopyrrolate - Spine Surgery, Reversal of Neuromuscular Blockade | Phase 4 | Completed | University of Missouri-Columbia | 118 | 2023-08-03 | 2026-10-07 |
| Evaluation of the Clinical Efficacy and Safety of BriTurn Injection or BrisTurn Prefilled Injection Reversal of Neuromuscular Blockade | Unknown | Hanlim Pharm. Co., Ltd. | 1500 | 2023-07-21 | 2024-02-07 | |
| Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145) Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Sugammadex 16 mg/kg - Reversal of Neuromuscular Blockade | Phase 4 | Completed | Merck Sharp & Dohme LLC | 344 | 2017-12-20 | 2020-10-08 |
Delayed Emergence from Anesthesia (3) · Arrhythmias, Cardiac (1) · Bradycardia (1) · Myasthenia Gravis (1) · Tachycardia (1) · Urinary Retention (1)
Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Postoperative Complications (3) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Cardiac Conduction System Disease (1) · Cardiovascular Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Heart Diseases (1) · Immune System Diseases (1) · Male Urogenital Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Nervous System Diseases (1)
Neostigmine (4) · Rocuronium (4) · Sugammadex (4) · Glycopyrrolate (2) · Pipecuronium (2) · Atropine (1) · Vecuronium Bromide (1)
Tamas Vegh, MD (2) · Beijing Tongren Hospital (1) · Fujian Shengdi Pharmaceutical Co., Ltd. (1) · Hanlim Pharm. Co., Ltd. (1) · Merck Sharp & Dohme LLC (1) · Universitas Padjadjaran (1) · University of Missouri-Columbia (1)
China (2) · Hungary (2) · United States (2) · Austria (1) · Denmark (1) · Germany (1) · Indonesia (1) · South Korea (1)
Boris Mraovic, MD, FASA (1) · Guyan Wang (1) · Sangseok Lee (1) · Tini T Maskoen, M.D. (1)
PMID 11339776, PMID 17264722, PMID 18946293, PMID 20375901, PMID 20683334, PMID 23599531, PMID 25192270, PMID 26086278, PMID 26508869, PMID 27324403, PMID 27463265, PMID 30219643, PMID 30875518, PMID 31124838, PMID 31421671, PMID 31744470, PMID 33917535, PMID 34226417, PMID 34711192, PMID 35322378, PMID 37763148
2017 (1)